About a year after regaining from F. Hoffman-La Roche Inc. the rights to Zenapax (daclizumab) in all rights except transplant rejection, Protein Design Labs Inc. signed a potential $205 million deal for Roche to co-develop and sell the Phase II compound for asthma and related respiratory diseases. (BioWorld Today) Read More
